Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.

Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...

In the phase 2 MIRO-CKD trial, investigators tested a novel MRA in combination with an SGLT2 inhibitor and included patients with higher serum potassium levels than 4.8 mmol/L at baseline and patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The eGFR slope improved in all but one patient not on a ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...